~ Record full year sales and adjusted EBITDA with strong organic growth ~ ~ Successful integration of recent acquisitions ~ Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, today announces its unaudited preliminary results for the year ended 31 December 2025. Read more…
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b […]
Lead programme based on a first‑in‑class small‑molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV‑positive head and neck cancer Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027 Progress is complemented with formation of world-class SAB, including leading experts in E3 […]
— Financing brings total funds committed to date to >$95 million — Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory diseases — Expands the leadership team with exceptional development executives to propel the clinical advancement of the pipeline Cambridge, UK, March […]
Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will be presenting at Redeye Theme Event: Commercialization in Life Science in Stockholm, at 10:15 AM CET on Friday 20 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending […]
